Status:

COMPLETED

A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

Lead Sponsor:

Pfizer

Conditions:

Pulmonary Disease, Chronic Obstructive

Eligibility:

All Genders

35-75 years

Phase:

PHASE1

PHASE2

Brief Summary

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Eligibility Criteria

Inclusion

  • GOLD criteria 2 to 4
  • 10 pack year history of smoking

Exclusion

  • Women of child bearing potential

Key Trial Info

Start Date :

December 1 2004

Trial Type :

INTERVENTIONAL

End Date :

December 1 2005

Estimated Enrollment :

136 Patients enrolled

Trial Details

Trial ID

NCT00163098

Start Date

December 1 2004

End Date

December 1 2005

Last Update

October 13 2006

Active Locations (28)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (28 locations)

1

Pfizer Investigational Site

Córdoba, Córdoba Province, Argentina, CP 5016

2

Pfizer Investigational Site

San Miguel de Tucumán, Pcia de Tucuman, Argentina, 4000

3

Pfizer Investigational Site

San Miguel de Tucumán, Pcia de Tucuman, Argentina

4

Pfizer Investigational Site

Rosario, Santa Fé, Argentina, 2000